The world’s first
long acting HIV fusion inhibitor. An amino acid synthesized peptide,
lyophilized powder for injection with shelf life 24
months. The API should be stored and transported at -20C, and the finished
product should be stored and transported at 2-8C. ALBUVIRTIDE only need to
be administered once per week, improves
the medication adherence, there is evidence that simplified regimens that
require fewer pills and lower dose frequencies improve adherence, missing even
a single dose in a 28-day reporting period has been shown to predict treatment
failure, the rapid replication and mutation rate of HIV means that not less
than 95% of adherence levels are required to achieve durable suppression of
viral load, of the patients suffering from AIDS, approximately only one-third
take their medication as prescribed, even when patients fully comprehend the
consequences of non-adherence
to medications,
adherence rates are suboptimal, suboptimal adherence may rapidly lead to
resistance, which can then be transmitted to other people. With drug
resistance, HIV medicines that used to suppress patients HIV are not effective
against the new drug-resistant HIV.
Small increases in adherence can result in significant improvements in
overall health, quality of life, and survival.Contact us for more information.Efficacy, US NIH research data indicates that ALBUVIRTIDE has better efficacy to lab virus strains and clinical epidemic strains than T20.Safety, the study shows that compared with regimens of 3-4 drugs, the combination of long acting HIV fusion inhibitor ALBUVIRTIDE and one other ART drug could offer simplified therapy with better safety and less drug-drug interaction.
CN
